HP 228: The compound had completed a Phase IIa dose tolerance trial

HP 228 is thought to modulate cytokine activity through the melanocortin-1 receptor and other

Read the full 147 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE